Drug-eluting stents to prevent stent thrombosis and restenosis

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Although first-generation drug-eluting stents (DES) have significantly reduced the risk of in-stent restenosis, they have also increased the long-term risk of stent thrombosis. This safety concern directly triggered the development of new generation DES, with innovations in stent platforms, polymers, and anti-proliferative drugs. Stent platform materials have evolved from stainless steel to cobalt or platinum-chromium alloys with an improved strut design. Drug-carrying polymers have become biocompatible or biodegradable and even polymer-free DES were introduced. New limus-family drugs (such as everolimus, zotarolimus or biolimus) were adopted to enhance stent performances. As a result, these new DES demonstrated superior vascular healing responses on intracoronary imaging studies and lower stent thrombotic events in actual patients. Recently, fully-bioresorbable stents (scaffolds) have been introduced, and expanding their applications. In this article, the important concepts and clinical results of new generation DES and bioresorbable scaffolds are described.

Original languageEnglish
Pages (from-to)87-104
Number of pages18
JournalExpert Review of Cardiovascular Therapy
Volume14
Issue number1
DOIs
Publication statusPublished - 2016 Jan 2

Fingerprint

Drug-Eluting Stents
Stents
Thrombosis
Polymers
Chromium Alloys
Pharmaceutical Preparations
Stainless Steel
Cobalt
Platinum
Blood Vessels
Safety

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

@article{3e30535f43414801b7e2c61a85340aa2,
title = "Drug-eluting stents to prevent stent thrombosis and restenosis",
abstract = "Although first-generation drug-eluting stents (DES) have significantly reduced the risk of in-stent restenosis, they have also increased the long-term risk of stent thrombosis. This safety concern directly triggered the development of new generation DES, with innovations in stent platforms, polymers, and anti-proliferative drugs. Stent platform materials have evolved from stainless steel to cobalt or platinum-chromium alloys with an improved strut design. Drug-carrying polymers have become biocompatible or biodegradable and even polymer-free DES were introduced. New limus-family drugs (such as everolimus, zotarolimus or biolimus) were adopted to enhance stent performances. As a result, these new DES demonstrated superior vascular healing responses on intracoronary imaging studies and lower stent thrombotic events in actual patients. Recently, fully-bioresorbable stents (scaffolds) have been introduced, and expanding their applications. In this article, the important concepts and clinical results of new generation DES and bioresorbable scaffolds are described.",
author = "Eui Im and Myeongki Hong",
year = "2016",
month = "1",
day = "2",
doi = "10.1586/14779072.2016.1112267",
language = "English",
volume = "14",
pages = "87--104",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "1",

}

Drug-eluting stents to prevent stent thrombosis and restenosis. / Im, Eui; Hong, Myeongki.

In: Expert Review of Cardiovascular Therapy, Vol. 14, No. 1, 02.01.2016, p. 87-104.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Drug-eluting stents to prevent stent thrombosis and restenosis

AU - Im, Eui

AU - Hong, Myeongki

PY - 2016/1/2

Y1 - 2016/1/2

N2 - Although first-generation drug-eluting stents (DES) have significantly reduced the risk of in-stent restenosis, they have also increased the long-term risk of stent thrombosis. This safety concern directly triggered the development of new generation DES, with innovations in stent platforms, polymers, and anti-proliferative drugs. Stent platform materials have evolved from stainless steel to cobalt or platinum-chromium alloys with an improved strut design. Drug-carrying polymers have become biocompatible or biodegradable and even polymer-free DES were introduced. New limus-family drugs (such as everolimus, zotarolimus or biolimus) were adopted to enhance stent performances. As a result, these new DES demonstrated superior vascular healing responses on intracoronary imaging studies and lower stent thrombotic events in actual patients. Recently, fully-bioresorbable stents (scaffolds) have been introduced, and expanding their applications. In this article, the important concepts and clinical results of new generation DES and bioresorbable scaffolds are described.

AB - Although first-generation drug-eluting stents (DES) have significantly reduced the risk of in-stent restenosis, they have also increased the long-term risk of stent thrombosis. This safety concern directly triggered the development of new generation DES, with innovations in stent platforms, polymers, and anti-proliferative drugs. Stent platform materials have evolved from stainless steel to cobalt or platinum-chromium alloys with an improved strut design. Drug-carrying polymers have become biocompatible or biodegradable and even polymer-free DES were introduced. New limus-family drugs (such as everolimus, zotarolimus or biolimus) were adopted to enhance stent performances. As a result, these new DES demonstrated superior vascular healing responses on intracoronary imaging studies and lower stent thrombotic events in actual patients. Recently, fully-bioresorbable stents (scaffolds) have been introduced, and expanding their applications. In this article, the important concepts and clinical results of new generation DES and bioresorbable scaffolds are described.

UR - http://www.scopus.com/inward/record.url?scp=84949730851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949730851&partnerID=8YFLogxK

U2 - 10.1586/14779072.2016.1112267

DO - 10.1586/14779072.2016.1112267

M3 - Review article

C2 - 26567863

AN - SCOPUS:84949730851

VL - 14

SP - 87

EP - 104

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 1

ER -